Cancer drug repurposed to fight Treatment-Related weight loss
NCT ID NCT06995508
Summary
This study is testing whether adding the medication olanzapine to standard care helps head and neck cancer patients maintain their weight and appetite during intense chemoradiation treatment. About 66 patients will be randomly assigned to receive either standard care alone or standard care plus daily olanzapine pills. The main goal is to see if olanzapine can prevent dangerous weight loss and improve patients' quality of life during this difficult treatment period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.